1. Home
  2. CTMX vs AFJK Comparison

CTMX vs AFJK Comparison

Compare CTMX & AFJK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • AFJK
  • Stock Information
  • Founded
  • CTMX 2008
  • AFJK 2023
  • Country
  • CTMX United States
  • AFJK United States
  • Employees
  • CTMX N/A
  • AFJK N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • AFJK
  • Sector
  • CTMX Health Care
  • AFJK
  • Exchange
  • CTMX Nasdaq
  • AFJK NYSE
  • Market Cap
  • CTMX 60.7M
  • AFJK 67.3M
  • IPO Year
  • CTMX 2015
  • AFJK 2023
  • Fundamental
  • Price
  • CTMX $1.99
  • AFJK $11.09
  • Analyst Decision
  • CTMX Buy
  • AFJK
  • Analyst Count
  • CTMX 2
  • AFJK 0
  • Target Price
  • CTMX $2.50
  • AFJK N/A
  • AVG Volume (30 Days)
  • CTMX 9.5M
  • AFJK 4.9K
  • Earning Date
  • CTMX 05-12-2025
  • AFJK 01-01-0001
  • Dividend Yield
  • CTMX N/A
  • AFJK N/A
  • EPS Growth
  • CTMX 128.27
  • AFJK N/A
  • EPS
  • CTMX 0.49
  • AFJK 0.28
  • Revenue
  • CTMX $147,557,000.00
  • AFJK N/A
  • Revenue This Year
  • CTMX N/A
  • AFJK N/A
  • Revenue Next Year
  • CTMX N/A
  • AFJK N/A
  • P/E Ratio
  • CTMX $4.90
  • AFJK $39.01
  • Revenue Growth
  • CTMX 23.81
  • AFJK N/A
  • 52 Week Low
  • CTMX $0.40
  • AFJK $10.24
  • 52 Week High
  • CTMX $2.81
  • AFJK $11.20
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 80.26
  • AFJK N/A
  • Support Level
  • CTMX $0.91
  • AFJK N/A
  • Resistance Level
  • CTMX $2.55
  • AFJK N/A
  • Average True Range (ATR)
  • CTMX 0.22
  • AFJK 0.00
  • MACD
  • CTMX 0.18
  • AFJK 0.00
  • Stochastic Oscillator
  • CTMX 87.53
  • AFJK 0.00

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About AFJK AIMEI HEALTH TECHNOLOGY CO LTD

Aimei Health Technology Co Ltd is a blank check company.

Share on Social Networks: